Bank of New York Mellon Corp Increases Stake in MediWound Ltd. (NASDAQ:MDWD)

Bank of New York Mellon Corp raised its holdings in shares of MediWound Ltd. (NASDAQ:MDWD) by 14.8% in the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 18,357 shares of the biopharmaceutical company’s stock after buying an additional 2,370 shares during the period. Bank of New York Mellon Corp owned about 0.17% of MediWound worth $285,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also added to or reduced their stakes in the business. Northern Trust Corp boosted its position in shares of MediWound by 94.6% in the fourth quarter. Northern Trust Corp now owns 144,768 shares of the biopharmaceutical company’s stock worth $2,577,000 after purchasing an additional 70,367 shares during the period. MGO One Seven LLC bought a new position in shares of MediWound in the fourth quarter worth approximately $216,000. Silverberg Bernstein Capital Management LLC boosted its position in shares of MediWound by 13.1% in the first quarter. Silverberg Bernstein Capital Management LLC now owns 103,944 shares of the biopharmaceutical company’s stock worth $1,613,000 after purchasing an additional 12,060 shares during the period. Yelin Lapidot Holdings Management Ltd. boosted its position in shares of MediWound by 0.8% in the first quarter. Yelin Lapidot Holdings Management Ltd. now owns 858,000 shares of the biopharmaceutical company’s stock worth $13,316,000 after purchasing an additional 6,639 shares during the period. Finally, Geode Capital Management LLC boosted its position in shares of MediWound by 3.6% in the fourth quarter. Geode Capital Management LLC now owns 98,710 shares of the biopharmaceutical company’s stock worth $1,757,000 after purchasing an additional 3,408 shares during the period. 46.83% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

MDWD has been the subject of a number of recent analyst reports. HC Wainwright set a $31.00 price target on shares of MediWound and gave the stock a “buy” rating in a research report on Thursday, May 22nd. Alliance Global Partners initiated coverage on shares of MediWound in a research report on Friday, May 2nd. They issued a “buy” rating and a $25.00 price target for the company. Oppenheimer initiated coverage on shares of MediWound in a research report on Monday, June 2nd. They issued an “outperform” rating and a $34.00 price target for the company. Finally, Wall Street Zen lowered shares of MediWound from a “hold” rating to a “sell” rating in a research report on Friday, July 18th. One analyst has rated the stock with a sell rating and four have assigned a buy rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $32.25.

MediWound Stock Performance

Shares of NASDAQ:MDWD opened at $18.37 on Tuesday. The firm has a fifty day moving average price of $20.22 and a 200 day moving average price of $18.64. MediWound Ltd. has a fifty-two week low of $14.14 and a fifty-two week high of $22.50. The firm has a market cap of $198.58 million, a price-to-earnings ratio of -8.79 and a beta of 0.21.

MediWound (NASDAQ:MDWD) last issued its earnings results on Wednesday, May 21st. The biopharmaceutical company reported ($0.07) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.65) by $0.58. The firm had revenue of $3.96 million during the quarter, compared to analyst estimates of $5.20 million. MediWound had a negative net margin of 110.45% and a negative return on equity of 74.12%. During the same quarter in the prior year, the business earned ($1.05) earnings per share. As a group, research analysts predict that MediWound Ltd. will post -2.66 earnings per share for the current year.

MediWound Company Profile

MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in United States, Europe, and internationally. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units.